CEO Today Healthcare Awards

www.ceotodaymagazine.com CEO Today Healthcare Awards 2019 17 USA ABOUT RENAUD DEHARENG Renaud was appointed as Curium’s CEO when the company was formed in early 2017, with a vision of developing the company into a global leader in nuclear medicine. Now the world’s largest vertically-integrated nuclear medicine company with an extensive portfolio of products, Curium operates in over 60 countries and provides life-saving diagnosis and treatment supporting more than 14 million patients per year. One of Renaud’s main achievements has been to unite a stand-out team of more than 2,000 members worldwide to take Curium through its vision and strategy, successfully establishing the organization as a trusted supplier of radiopharmaceuticals. Renaud is now leveraging Curium’s unique global infrastructure and proven industry experience to serve its clients with an emphasis on compliance, service reliability, operational excellence, and new product development. Renaud cites the formation of Curium as one of the accomplishments as CEO that he is most proud of, explaining that: “Nuclear medicine has existed for over 60 years, and our biggest success has been to pull together Curium and to create a player in the industry which can provide clients with reliable supply for a comprehensive portfolio of high-quality nuclear medicine products. This combination of capabilities was not accessible to clients before Curium”. Looking ahead to the future, Renaud plans to drive Curium forward and launch several innovative diagnostic and therapeutic products in the next few years: “Curium is a game-changer in terms of bringing innovation to nuclear medicine: we have the capability to deliver the current nuclear medicine products better, faster and with higher levels of reliability and compliance, which is necessary as a starting point. We are now moving and using this infrastructure, assets, skills and people to bring new solutions into the nuclear medicine market”. Renaud has been part of Curium and its predecessors’ companies since 2009. Prior to his current role, he was Group COO and CEO Europe. Previously, he served in Arthur Andersen’s strategic consulting division, which he joined after graduating from the UK’s Warwick Business School. Originally from Belgium, Renaud is married and has three children. In his spare time, he competes in triathlons and enjoys kite surfing. RENAUD DEHARENG CEO of CURIUM FIRM PROFILE Curium is the world’s leading provider of nuclear medicine, with a singular focus to develop, manufacture and supply world-class radioactive pharmaceutical products to customers around the globe. Specializing in the production and supply of radioactive tracers used in nuclear medicine, Curium assists in the accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases. Drawing on over 100 years of combined experience, Curium aims to drive the nuclear medicine industry forward through excellence, reliability and unparalleled service. Proudly serving over 6,000 customers across the globe, the company delivers potentially life- saving products to over 14 million patients per year across more than 60 countries. Some of Curium’s notable achievements include: ● An innovative portfolio of over 50 radiopharmaceutical products, uniquely offering both Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) solutions. ● First supplier to fully convert from highly enriched uranium (HEU), to now offer 100% low enriched uranium (LEU) generators to the world market. ● The launch of Xenon Xe133 Gas, a critical agent for the evaluation of pulmonary function and lung imaging. ● The development of five other new products between 2018 and 2019, focusing on key areas of cancer diagnosis and other disease states. ● Through acquisition, Curium expanded its PET network to 26 sites world-wide, executed agreements for the development and distribution of new PET diagnostic agents and added new products to the group portfolio. In the coming years, Curium ambitions to expand its presence in Asiawherenuclearmedicineisstillinitsearlystagesandparticipate in the development and distribution of radiopharmaceutical products for therapeutic indications. The group will continue to strive towards bringing to physicians and hospitals innovative radiopharmaceuticals, to address unmet needs, for the benefit of patients in the oncology, cardiology and neurology indications. Putting patient care at the heart of our company’s mission, Curium is focused on delivering an uninterrupted supply of world- class products that empower our customers to improve health outcomes and lives going forward. Visit our website to learn more www.curiumpharma.com Contact Curium at contactus@curiumpharma.com